15038 studies
: Semaglutide and Liraglutide are medications in the Glucagon-like peptide-1 agonists (GLP-1 RAs) class used to manage type 2 diabetes mellitus and obesity in Saudi Arabia. Although the 1.0 mg once weekly dosage of Semaglutide does not have a labeled…
AIMS: Individuals with type 1 diabetes are at high risk of cardiovascular disease (CVD) and chronic kidney disease (CKD) even with optimal glycaemic control. The Steno 1 study will test a strategy of intensified care based on multifactorial intervent…
OBJECTIVE: To encourage continued research of the delayed gastric emptying effect of glucagon-like peptide-1 receptor agonists and its effect on absorption of orally administered estrogen. METHODS: A case is reported of a 51-year-old postmenopausal f…
OBJECTIVE: In the Evaluate Renal Function With Semaglutide Once Weekly (FLOW) trial, semaglutide reduced the risk of major kidney and cardiovascular (CV) outcomes and all-cause mortality in people with type 2 diabetes (T2D) and chronic kidney disease…
: Semaglutide, a glucagon-like peptide-1 receptor (GLP-1R) agonist, is a well-established pharmacologic agent for inducing weight loss in individuals with obesity and is prescribed regardless of type 2 diabetes mellitus (DM) status. However, it remai…
: Semaglutide (SEMA) has shown potential benefits in metabolic dysfunction-associated steatotic liver disease (MASLD). This large real-world study aimed to evaluate the effects of SEMA on MASLD patients' clinical outcomes and liver-related complicati…
Sex differences in type 2 diabetes (T2D) are a growing area of diabetes research. No data have been reported on sex differences with oral semaglutide (oSEMA) in a real-world setting.: We included people with T2D who started treatment with oSEMA in ro…
Semaglutide, a GLP-1 receptor agonist, has shown promising nephroprotective effects in clinical trials, though real-world data on its long-term impact on renal function in high-risk diabetic nephropathy patients remain scarce.We conducted a multicent…
BACKGROUND/AIMS: There is uncertainty regarding the hepatic efficacy of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in metabolic dysfunction-associated steatotic liver disease (MASLD) or steatohepatitis (MASH). We performed a meta-analysis o…
This article summarizes the top 20 research studies of 2024 identified as POEMs (patient-oriented evidence that matters). Based on a network meta-analysis, the oral antibiotics most likely to be effective for community-acquired pneumonia are telithro…
BACKGROUND: Artificial intelligence (AI) chatbots have shown competency in a range of areas, including clinical note taking, diagnosis, research, and emotional support. An obesity epidemic, alongside a growth in novel injectable pharmacological solut…
As obesity increases in the global population, it is important to recognize that obesity is not a willpower failure but a chronic disease regulated by genetic, environmental, and hormonal control of energy balance. Obesity is also caused by social an…
BACKGROUND: Obesity poses a significant public health and economic challenge in the United States (U.S.), with rising prevalence, particularly among individuals enrolled in Medicaid-the nation's public health insurance program for low-income populati…
BACKGROUND: Atrial fibrillation (AF) stands as the most prevalent type of arrhythmia, affecting approximately 60 million individuals world-wide. Although antiarrhythmic drugs (AADs) remain the gold standard for AF treatment, glucagon-like peptide-1 r…
Euglycemic diabetic ketoacidosis (EDKA) is an uncommon life-threatening condition increasingly recognized in patients treated with sodium-glucose co-transporter 2 (SGLT2) inhibitors. Its diagnosis is often delayed due to the absence of significant hy…
AIM: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for type 2 diabetes, chronic weight management and obstructive sleep apnoea (in the US). To assess the contribution of…